{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 408782146
| IUPAC_name = (''RS'')-5-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,3-diol
| image = Orciprenaline.svg
| width =
| chirality = [[Racemic mixture]]
| USAN = Metaproterenol

<!--Clinical data-->
| tradename =  
| Drugs.com = [http://www.drugs.com/monograph/metaproterenol-sulfate.html monograph]
| MedlinePlus = a682084
| pregnancy_AU = A
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = Inhalation ([[Metered-dose inhaler|MDI]]) and [[Tablet (pharmacy)|tablets]]

<!--Pharmacokinetic data-->
| bioavailability = 3% if inhaled, 40% if taken orally
| protein_bound =  
| metabolism = [[Gastrointestinal tract|Gastrointestinal]] and [[liver|hepatic]]
| elimination_half-life = 6 hours

<!--Identifiers-->
| IUPHAR_ligand = 7250
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 586-06-1
| ATC_prefix = R03
| ATC_suffix = AB03
| ATC_supplemental =  {{ATC|R03|CB03}}<br>{{ATC|R03|CB53}}
| PubChem = 4086
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00816
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3944
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 53QOG569E0
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08300
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 82719
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 776

<!--Chemical data-->
| C=11 | H=17 | N=1 | O=3
| molecular_weight = 211.258 g/mol
| smiles = Oc1cc(cc(O)c1)C(O)CNC(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LMOINURANNBYCM-UHFFFAOYSA-N
| solubility = 9.7
}}

'''Orciprenaline''', also known as '''metaproterenol''', is a [[bronchodilator]] used in the treatment of [[asthma]].<ref>{{cite journal |title = DrugBank 3.0: a comprehensive resource for omics research on drugs |vauthors=Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS |journal = Nucleic Acids Res. |year = 2011 |volume = 39 |issue = Database issue |pages = D1035-41 | pmid =21059682 |doi=10.1093/nar/gkq1126 |pmc=3013709}}</ref><ref>{{cite journal |title = DrugBank: a knowledgebase for drugs, drug actions and drug targets |vauthors=Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M |journal = Nucleic Acids Res |year = 2008 |volume = 36 |issue = Database issue |pages = D901-6 |pmid = 18048412 |doi=10.1093/nar/gkm958 |pmc=2238889}}</ref> Orciprenaline is a moderately selective [[Beta2-adrenergic agonist|β<sub>2</sub> adrenergic receptor agonist]] that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors. The pharmacologic effects of β adrenergic [[agonist]] drugs, such as orciprenaline, are at least in part attributable to stimulation through β adrenergic receptors of intracellular [[adenylyl cyclase]], the enzyme which catalyzes the conversion of [[Adenosine triphosphate|ATP]] to [[Cyclic adenosine monophosphate|cAMP]]. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.

== Possible side effects ==
* tremor
* nervousness
* dizziness
* weakness
* headache
* nausea
* tachycardia

;Rare side effects that could be life-threatening
* increased difficulty breathing
* rapid or increased heart rate
* irregular heartbeat
* chest pain or discomfort

== Brand names ==
* Alupent
* Metaprel
* Orcibest

== References ==
{{reflist}}

{{Asthma_and_copd rx}}
{{Adrenergics}}
{{Phenethylamines}}

[[Category:Chemical substances for emergency medicine]]
[[Category:Phenethylamines]]


{{respiratory-system-drug-stub}}